Does Dapagliflozin damage kidney function?

Dapagliflozin is a drug used to treat type 2 diabetes. It belongs to a class of drugs called SGLT-2 inhibitors (sodium-glucose cotransporter 2 inhibitors). SGLT-2Inhibitors reduce the reabsorption of glucose by the renal tubules by inhibiting the SGLT-2 channel in the kidney, thereby increasing the excretion of glucose in the urine and reducing blood sugar levels.

WhileSGLT-2inhibitors are excellent at lowering blood sugar and treating type 2 diabetes, they are also associated with some risk factors that affect kidney function. Specifically, the use of SGLT-2 inhibitors may result in mild renal impairment. However, this is usually reversible, and kidney function may return to previous levels after stopping the drug.

Research suggests that users of SGLT-2 inhibitors may experience a mild decrease in kidney function for a period of time after starting treatment. This is called drug-induced transient renal insufficiency (acute kidney injury), and is usually caused by the drug affecting the regulatory mechanisms of the kidney tubules, resulting in changes in fluid and electrolytes in the body. However, this decrease in kidney function is usually temporary and gradually recovers after the drug is stopped.

Nonetheless, if you are considering or using dapagliflozin or otherSGLT-2inhibitors, you should do so under the supervision of a physician and have your kidney function monitored regularly. Your doctor will evaluate the risks and benefits based on your specific situation to ensure your diabetes management program is safe and effective. Do not adjust your medication dosage or stop using it unless directed by your doctor.

Dapagliflozin has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price is relatively cheap. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies.